Using GS9350 rather than Ritonavir will allow GILD to have all the rights to a single once-daily treatment for HIV, with potentially a smaller pill size (GS9350 will replace 100mg Ritonavir), and a new PK enhancer which is devoid of HIV activity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.